Literature DB >> 27934382

Enantioselective, Copper-Catalyzed Alkynylation of Ketimines To Deliver Isoquinolines with α-Diaryl Tetrasubstituted Stereocenters.

Srimoyee Dasgupta1, Jixin Liu1, Clarissa A Shoffler1, Glenn P A Yap1, Mary P Watson1.   

Abstract

An enantioselective, copper-catalyzed alkynylation of cyclic α,α-diaryl ketiminium ions has been developed to deliver isoquinoline products with diaryl, tetrasubstituted stereocenters. The success of this reaction relied on identification of Ph-PyBox as the optimal ligand, i-Pr2NEt as the base, and CHCl3 as the solvent. A broad scope and functional group tolerance were observed. Notably, the use of both aryl and silyl acetylenes results in high yields and enantioselectivities. Mechanistic experiments are consistent with a dimeric or higher order catalyst.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27934382      PMCID: PMC5161116          DOI: 10.1021/acs.orglett.6b02787

Source DB:  PubMed          Journal:  Org Lett        ISSN: 1523-7052            Impact factor:   6.005


  30 in total

1.  Enantioselective construction of quaternary stereocenter through a Reissert-type reaction catalyzed by an electronically tuned bifunctional catalyst: efficient synthesis of various biologically significant compounds.

Authors:  K Funabashi; H Ratni; M Kanai; M Shibasaki
Journal:  J Am Chem Soc       Date:  2001-10-31       Impact factor: 15.419

2.  Copper-catalyzed coupling of pyridines and quinolines with alkynes: a one-step, asymmetric route to functionalized heterocycles.

Authors:  Daniel A Black; Ramsay E Beveridge; Bruce A Arndtsen
Journal:  J Org Chem       Date:  2008-01-24       Impact factor: 4.354

3.  Discovery of an orally active non-peptide fibrinogen receptor antagonist.

Authors:  H U Stilz; B Jablonka; M Just; J Knolle; E F Paulus; G Zoller
Journal:  J Med Chem       Date:  1996-05-24       Impact factor: 7.446

4.  Asymmetric synthesis of (triaryl)methylamines by rhodium-catalyzed addition of arylboroxines to cyclic N-sulfonyl ketimines.

Authors:  Takahiro Nishimura; Akira Noishiki; Gavin Chit Tsui; Tamio Hayashi
Journal:  J Am Chem Soc       Date:  2012-03-08       Impact factor: 15.419

5.  Construction of Optically Active Quaternary Propargyl Amines by Highly Enantioselective Zinc/BINOL-Catalyzed Alkynylation of Ketoimines.

Authors:  Gaochao Huang; Zengsheng Yin; Xingang Zhang
Journal:  Chemistry       Date:  2013-07-15       Impact factor: 5.236

6.  Enantioselective addition of terminal alkynes to isolated isoquinoline iminiums.

Authors:  Alexander M Taylor; Stuart L Schreiber
Journal:  Org Lett       Date:  2006-01-05       Impact factor: 6.005

Review 7.  Privileged scaffolds for library design and drug discovery.

Authors:  Matthew E Welsch; Scott A Snyder; Brent R Stockwell
Journal:  Curr Opin Chem Biol       Date:  2010-03-18       Impact factor: 8.822

8.  Enantioselective addition of activated terminal alkynes to 1-acylpyridinium salts catalyzed by Cu-Bis(oxazoline) complexes.

Authors:  Zhankui Sun; Shouyun Yu; Zuoding Ding; Dawei Ma
Journal:  J Am Chem Soc       Date:  2007-07-11       Impact factor: 15.419

9.  Hydroxorhodium/chiral diene complexes as effective catalysts for the asymmetric arylation of 3-aryl-3-hydroxyisoindolin-1-ones.

Authors:  Takahiro Nishimura; Akira Noishiki; Yusuke Ebe; Tamio Hayashi
Journal:  Angew Chem Int Ed Engl       Date:  2013-01-10       Impact factor: 15.336

Review 10.  beta-Phenylethylamines and the isoquinoline alkaloids.

Authors:  Kenneth W Bentley
Journal:  Nat Prod Rep       Date:  2004-05-05       Impact factor: 13.423

View more
  2 in total

1.  Further Developments and Applications of Oxazoline-Containing Ligands in Asymmetric Catalysis.

Authors:  Robert Connon; Brendan Roche; Balaji V Rokade; Patrick J Guiry
Journal:  Chem Rev       Date:  2021-05-21       Impact factor: 60.622

2.  Enantioselective synthesis of α-tetrasubstituted (3-indolizinyl) (diaryl)methanamines via chiral phosphoric acid catalysis.

Authors:  Jialing Zhong; Rihuang Pan; Xufeng Lin
Journal:  RSC Adv       Date:  2022-07-15       Impact factor: 4.036

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.